Efficacy of secukinumab in treating psoriasis

The interleukin-17A (IL-17A) inhibitor secukinumab shows promise as a treatment option for patients with moderate to severe psoriasis

Researchers evaluated secukinumab in two phase III, double-blind 52-week trials, with 738 patients in the ERASURE study and 1,306 patients in the FIXTURE study.

Patients were randomly assigned to subcutaneous secukinumab at a dose of 300mg or 150mg, or placebo, or, in the FIXTURE study, 50mg etanercept.

About 80% of patients treated with 300mg secukinumab achieved PASI 75 at week 12, compared with 67-71.6% of those treated with 150mg secukinumab, and 44% of those treated with etanercept.

Secukinumab was found to clear skin more quickly than etanercept, with an average 50% reduction in affected skin and severity of psoriasis after three weeks compared with seven weeks with etanercept.

The incidence of side-effects in patients treated with secukinumab was comparable with those in patients treated with etanercept.

Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. New Engl J Med 2014; 371: 326-38


Read these next

2 CPD credits: Clinical Review: Psoriasis

2 CPD credits: Clinical Review: Psoriasis

This condition can have a significant psychological...

Efficacy and safety of etanercept

Etanercept was the first TNF-alpha inhibitor to be...

1 CPD credit: Second-line treatment for patients with psoriasis

1 CPD credit: Second-line treatment for patients with psoriasis

Options include phototherapy and non-biological systemic...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.